Skip to main content

Table 1 Baseline characteristics of rheumatoid arthritis patients at study entry

From: Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis

Patients

Responder

Nonresponder

P value

Number of patients

31

19

 

Sex (male:female)

7:24

4:15

0.61

Mean (range) age (years)

55.8 (41 to 75)

55.9 (40 to 71)

0.97

Cardiovascular risk factors (≥1, % positive)

51.1

65.4

0.12

IgM-RF (% positive)

54.8

31.6

0.17

Anti-CCP (% positive)

64.5

31.6

0.15

Mean (standard deviation) DAS28

4.82 (±1.19)

5.30 (±1.55)

0.22

Mean (range) CRP (mg/l)

10.9 (2.0 to 114.5)

11.4 (2.0 to 80.7)

0.93

Mean (range) disease duration (years)

6.92 (2 to 29)

5.4 (1 to 19)

0.84

Therapy

   

 Corticosteroids

23

11

 

 DMARDs

   

  Methotrexate

24

15

 

  Leflunomide

7

4

 
  1. Anti-CCP, anti-cyclic citrullinated peptide antibodies; CRP, C-reactive protein; DAS28, Disease activity score in 28 joints at study visit V1; DMARD, disease-modifying antirheumatic drug; RF, rheumatoid factor.